GlaxoSmithKline plc (LON:GSK) had its price target cut by Jefferies Group LLC from GBX 1,540 ($20.26) to GBX 1,450 ($19.07) in a research report released on Thursday. They currently have a buy rating on the stock.

GSK has been the topic of several other reports. Investec lowered shares of GlaxoSmithKline plc to a hold rating and cut their price target for the stock from GBX 1,800 ($23.67) to GBX 1,390 ($18.28) in a report on Monday, November 6th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.99) price target on shares of GlaxoSmithKline plc and gave the stock a buy rating in a report on Tuesday, August 8th. Deutsche Bank AG set a GBX 1,610 ($21.18) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a report on Tuesday, August 8th. Citigroup Inc. reaffirmed a neutral rating on shares of GlaxoSmithKline plc in a report on Thursday, November 9th. Finally, Societe Generale reaffirmed a sell rating on shares of GlaxoSmithKline plc in a report on Thursday, November 9th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline plc has an average rating of Hold and an average target price of GBX 1,569.75 ($20.65).

Shares of GlaxoSmithKline plc (LON GSK) traded down GBX 10 ($0.13) during trading hours on Thursday, reaching GBX 1,308 ($17.20). 6,441,460 shares of the company were exchanged, compared to its average volume of 9,720,000. GlaxoSmithKline plc has a 52 week low of GBX 1,311 ($17.24) and a 52 week high of GBX 1,724.50 ($22.68).

GlaxoSmithKline plc (LON:GSK) last issued its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, topping analysts’ consensus estimates of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline plc had a net margin of 17.79% and a return on equity of 461.88%.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-given-new-gbx-1450-price-target-at-jefferies-group-llc/1710653.html.

The firm also recently declared a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be issued a GBX 19 ($0.25) dividend. This represents a yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th.

In other news, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was acquired at an average price of GBX 1,527 ($20.08) per share, for a total transaction of £16,430.52 ($21,610.57). Also, insider Urs Rohner acquired 473 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was purchased at an average price of GBX 1,518 ($19.97) per share, with a total value of £7,180.14 ($9,443.82). In the last quarter, insiders acquired 1,576 shares of company stock valued at $2,400,376.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.